CagriSema added to basal insulin tested in phase 3 REIMAGINE 3 trial
The Lancet published results for the cagrilintide-semaglutide combination in adults with type 2 diabetes already on basal insulin.
MH
By Maren Holt · Senior Reporter, GLP-1
Jun 7 03:00 ETSource: The Lancet
The wire
- 01REIMAGINE 3 was a randomised, double-blind, placebo-controlled, multicentre phase 3 study of CagriSema as an add-on to basal insulin in type 2 diabetes.
- 02The amylin analog plus GLP-1 combination is Novo's answer to tirzepatide, and insulin add-on data shape where it fits in diabetes care.
- 03Full efficacy and safety figures should be read in the published paper before drawing conclusions about comparative benefit.
From the source
Read at thelancet.comCagrilintide–semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study